U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year option periods entered into in May 2021. The contract supports DLA's counterfeit mitigation initiatives and product verification and testing programs specific to FSC 5962 microcircuits. The maximal value of the indefinite delivery contract is $1.04 million over an up to five-year performance term. The option-year exercise continues Applied DNA's support of DLA's counterfeit mitigation program, which has been running since 2014.
應用DNA科學公司(Applied DNA Sciences,納斯達克:APDN)是一家PCR基於DNA技術的領導者。今天宣佈,美國國防後勤局(DLA)行使了2021年5月簽訂的爲期三年的基礎合同中的兩個一年期權期限中的第一個一年期。該合同支持DLA的仿冒緩解措施和針對FSC 5962型微電路的產品驗證和測試計劃。無限交付合同的最大價值在五年執行期內爲104萬元。該選擇年繼續應用DNA支持DLA的仿冒緩解計劃,該計劃自2014年以來一直在運行。
"We are pleased to enable DLA to maintain program continuity in service of the nation's defense capabilities and further reinforce the application of our forensic DNA mark as a secure, high-resolution taggant to track provenance and ensure authenticity," said Judy Murrah, chief operating officer of Applied DNA.
"我們很高興能夠幫助DLA維持計劃連續性,以服務於國家的防禦能力,並進一步強化我們的法醫DNA標記應用作爲一種安全、高分辨率標記,用於跟蹤由我們認證的貨源,並確保貨源的真實性。"Applied DNA的首席運營官朱迪·穆拉(Judy Murrah)說。
About Applied DNA Sciences
關於Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
應用DNA科學是一家生物技術公司,開發用於生產和檢測脫氧核糖核酸("DNA ")的技術。利用聚合酶鏈式反應("PCR ")實現DNA的生產和檢測,我們在三個主要業務市場運營: (i)用於核酸基因治療製劑的酶催化合成DNA以及通過最近收購的Spindle Biotech,Inc.("Spindle ")提供專有的RNA聚合酶("RNAP ")用於生產mRNA治療品; (ii)在分子診斷和遺傳測試服務中檢測DNA和RNA。 (iii)爲工業供應鏈安全服務製造和檢測DNA。
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
請訪問adnas.com了解更多信息。關注我們的X和領英。加入我們的郵件列表。
Forward-Looking Statements
前瞻性聲明
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the unknown future demand by the U.S. Defense Logistics Agency for its supply chain traceability service, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023 and Quarterly Report on Form 10-Q filed on February 8, 2024, and May 10, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
本新聞稿中的應用DNA的陳述可能具有"前瞻性"特徵,其屬於1933年證券法第27A條,1934年證券交易法第21E條以及1995年私人證券訴訟改革法之內。前瞻性聲明描述了應用DNA的未來計劃、投資理念、策略和期望,並建立在一些假設之上,涉及若干風險和不確定因素,其中許多因素超出了應用DNA的控制範圍。由於應用DNA的淨損失歷史、有限的財務資源、美國國防後勤局對其供應鏈可追溯性服務的未知未來需求,以及時間點的不同,實際結果可能會與預期有所不同,詳情請參見應用DNA於2023年12月7日修訂的年報第10-k表、以及2024年2月8日、5月10日提交的季度報表和其它提交證券交易委員會的報表,網址爲www.sec.gov。應用DNA沒有義務公開更新任何前瞻性聲明,以反映此後的新信息、事件或情況,除非法律另有要求。
Contacts:
聯繫人:
Applied DNA Sciences
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Web:
Twitter: @APDN
Applied DNA Sciences
投資者關係聯繫人:Sanjay M. Hurry,917-733-5573,sanjay.hurry@adnas.com
網站:
Twitter:@APDN
SOURCE: Applied DNA Sciences, Inc.
SOURCE: Applied DNA Sciences, Inc.